奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较

目的 比较奥沙利铂联合替吉奥（SOX方案）和吉西他滨联合顺铂（GP方案）治疗晚期三阴性乳腺癌的疗效和不良反应。方法 晚期三阴性乳腺癌患者随机分别接受多周期SOX方案（SOX 组，63例）和GP方案（GP组，57例）化疗。评价两组疗效和不良反应。结果 SOX组与GP组的总有效率（RR）分别为34.9％与35.1％，疾病控制率（DCR）为68.3％与70.2％，差异无统计学意义（P>0.05）；中位进展时间分别为9.5月与8.1月，差异有统计学意义（P=0.033）；1年生存率分别为69.8％和63.2％，总生存时间（OS）分别为19.5月与18.7月，差异无统计学意义（P=0.554、0.207）。常见的不良反应相似，其中腹泻、肝功能损害、外周神经毒性和手足综合征发生率SOX组明显高于GP组，血小板减少、恶心/呕吐、肾毒性和皮疹发生率GP组明显高于SOX组（P<0.05）。结论 奥沙利铂联合替吉奥、吉西他滨联合顺铂方案治疗晚期三阴性乳腺癌均安全、有效，不良反应耐受。

Clinical Efficacy and Toxicities of Oxaliplatin plus S-1(SOX) and Gemcitabine plus Cisplatin (GP) Regimens on Advanced Triple-negative Breast Cancer Patients

Objective To compare the curative effect and toxicities of oxaliplatin combined with S-1 (SOX) and gemcitabine combined with cisplatin (GP) on advanced triple-negative breast cancer(TNBC) patients. Methods Advanced TNBC patients randomly accepted several cycles of SOX regimen(SOX) (n=63) and GP regimen(GP) (n=57). The efficacy and toxicity were observed between two regimens. Results The total response rates (RR) were 34.9% in SOX group and 35.1% in GP group. The disease control rates(DCR) were 68.3% in SOX group and 70.2% in GP group, respectively (P>0.05); the median time to progression were 9.5 months in SOX group and 8.1 months in GP group (P=0.033); 1-year survival rates were 69.8% and 63.2%, and the overall survival(OS) was 19.5 and 18.7 months, respectively, without any statistically significant difference (P=0.554, 0.207). Adverse reactions were similar between the two groups. The incidence of diarrhea, liver function damage, peripheral nerve toxicity and hand-foot syndrome in SOX group were greater than those in GP group; the incidence of thrombocytopenia, nausea/vomiting, renal toxicity and skin rash in GP group were greater than those in SOX group (P<0.05). Conclusion Both SOX and GP regimens are safe, effective and tolerable in treating advanced TNBC patients.